Vertex Pharmaceuticals Inc. stock rises Tuesday, still underperforms market
This was the stock's third consecutive day of gains.
Vertex Pharmaceuticals Inc (VRTX) Stock: Analyzing Its Quiet Power
Vertex Pharmaceuticals Inc (VRTX) stock saw a modest uptick, ending the day at $408.18 which represents a slight increase of $2.91 or 0.72% from the prior close of $405.27. The stock opened at $401.53 and touched a low of $401.
Vertex Pharmaceuticals (NASDAQ:VRTX) Given New $430.00 Price Target at Scotiabank
Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its target price hoisted by Scotiabank from $426.00 to $430.00 in a research report released on Monday morning,Benzinga reports. They currently have a sector perform rating on the pharmaceutical company’s stock.
Vertex Pharmaceuticals Stock Dives After Mixed Drug Study Results
Key Takeaways Vertex Pharmaceuticals shares sank Thursday after the company reported mixed results in a Phase 2 drug trial to treat lumbosacral radiculopathy (LSR), which causes leg and back pain.The company said the trial of suzetrigine met its primary endpoint in reducing pain,
Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $408.18, denoting a +0.72% change from the preceding trading day.
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day
This was the stock's second consecutive day of gains.
Shareholder Rights Advocates at Levi & Korsinsky Investigate Vertex Pharmaceuticals Incorporated (VRTX) Regarding Possible Securities Fraud Violations
NEW YORK, NY / ACCESSWIRE / December 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
Should You Buy Vertex Pharmaceuticals on the Dip Before Potentially Enormous News in January 2025?
Vertex Pharmaceuticals (NASDAQ: VRTX) was on track to become one of this year's biotech winners, with the shares climbing 27% ...
Vertex wins approval for new once-daily CF drug
Vertex Pharmaceuticals Inc. notched two FDA victories late Friday for its cystic fibrosis medicines, increasing the number of ...
FiercePharma2d
Vertex snags FDA nod for once-daily cystic fibrosis triplet Alyftrek as switch from Trikafta kicks off
As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has ...
BioSpace2d
Vertex Wins FDA Approval for New Cystic Fibrosis Option but Stock Still Down
The new combination, dubbed Alyftrek, is designed to improve on the Trikafta, a product that generated sales of $8.9 billion ...
Zacks.com on MSN1d
Top Stock Reports for T-Mobile, Toyota Motor & Vertex Pharmaceuticals
Today's Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc. (TMUS), Toyota Motor ...
Vertex Pharmaceuticals price target lowered to $500 from $503 at JPMorgan
JPMorgan lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $500 from $503 and keeps an Overweight rating on the shares.
AFP2d
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference ...